Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. Objectives This study evaluated the potential of plasma β-amyloid (Aβ) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years. Design Total plasma Aβ42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern. Results Significant lower TP42/40 ratio was found in a-MCI patients compared to CN. Moreover, a-MCIs with a high-risk FDG-PET pattern for AD showed even lower plasma ratio levels. Low TP42/40 at baseline increased the risk of progression to dementia by 70%. Furthermore, TP42/40 was inversely associated with neocortical amyloid deposition (measured with PiB-PET) and was concordant with the AD biomarker profile in cerebrospinal fluid (CSF). Conclusions TP42/40 demonstrated value in the identification of individuals suffering a-MCI, in the prediction of progression to dementia, and in the detection of underlying AD pathology revealed by FDG-PET, Amyloid-PET and CSF biomarkers, being, thus, consistently associated with all the well-established indicators of AD.

What this study adds

Evidence grade: Low

The record lists 145 participants. A lower plasma Aβ42/40 ratio was found in people with amnestic mild cognitive impairment compared with cognitively normal individuals and was linked to a 70% increased risk of progressing to dementia. The ratio also matched amyloid PET and cerebrospinal fluid biomarker findings, suggesting it may help identify early Alzheimer's disease in screening.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Pérez-Grijalba, V., Romero, J., Pesini, P., Sarasa, L., Monleón, I., San-José, I., et al. (2019). Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study. The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2018.41

Vancouver

Pérez-Grijalba V, Romero J, Pesini P, Sarasa L, Monleón I, San-José I, et al. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study. The journal of prevention of Alzheimer's disease. 2019. doi:10.14283/jpad.2018.41. PMID: 30569084.

BibTeX

@article{perezgrijalba2019-30569084,
  author  = {Pérez-Grijalba, V. and Romero, J. and Pesini, P. and Sarasa, L. and Monleón, I. and San-José, I. and Arbizu, J. and Martínez-Lage, P. and others},
  title   = {{Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2019},
  doi     = {10.14283/jpad.2018.41},
  pmid    = {30569084},
  url     = {https://doi.org/10.14283/jpad.2018.41}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

A lower plasma Aβ42/40 ratio was found in people with amnestic mild cognitive impairment compared with cognitively normal individuals and was linked to a 70% increased risk of progressing to dementia. The ratio also matched amyloid PET and cerebrospinal fluid biomarker findings, suggesting it may help identify early Alzheimer's disease in screening.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 47 of the 96 points it could be judged on, which is 49 of 100. Total 49 of 100.47 of the 96 points we could judge = 49 of 100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 47 of the 96 points we could judge it on, which is 49 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease)
Journal's citation record 0 / 4 The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 2 / 4 145 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 131 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 14.6 citations a year over 9 year(s) since 2019
Impact for its field and year 3 / 6 Cited 5.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 3 / 4 Cited 88 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author M. Sarasa holds only 5 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Clinica Universidad de Navarra: institution h-index 435 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30569084)
Free to read 2 / 2 Free to read
Points 47 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 47 of the 96 points we could judge it on is 49 out of 100.
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Mild cognitive impairment from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →